Johnson & Johnson loses ruling over patent for prostate cancer drug Zytiga
Johnson & Johnson’s patent on the prostate-cancer drug Zytiga is invalid, a federal judge in New Jersey ruled Friday, clearing the way for generic competitors. The decision was a victory for generic-drug companies including Teva Pharmaceutical Industries Ltd., Mylan NV, and Amneal Pharmaceuticals Inc. It’s the second blow for J&J on the patent — a […]
from The Financial ExpressThe Financial Express https://ift.tt/2zak8H9
via IFTTT
from The Financial ExpressThe Financial Express https://ift.tt/2zak8H9
via IFTTT
Post a Comment